Article

How Are We Evaluating the Cost-Effectiveness of Companion Biomarkers for Targeted Cancer Therapies? A Systematic Review

2021-01-14

Abstract excerpt

<h4>Background: </h4> Despite the increasing economic assessment of biomarker-guided therapies, no clear agreement exists whether existing methods are sufficient or whether different methods might produce different cost-effectiveness results. This study aims to examine current practices of modeling companion biomarkers when assessing the cost-effectiveness of targeted cancer therapies. It highlights the challenges...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9f7a0704-62b1-5f71-bbe0-4009b6143642
DOI: 10.21203/rs.3.rs-139157/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

How Are We Evaluating the Cost-Effectiveness of Companion Biomarkers for Targeted Cancer Therapies? A Systematic ReviewDOI 10.21203/rs.3.rs-139157/v1Read

Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review.Semantic proximity Read

Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.Semantic proximity Read

Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.Semantic proximity Read

Statistical and practical considerations for clinical evaluation of predictive biomarkers.Semantic proximity Read

Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea.Semantic proximity Read

Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patientsSemantic proximity Read

Micro-costing Diagnostics in Oncology: From Single-Gene Testing to Whole Genome SequencingSemantic proximity Read

Systematic Review of cost-effectiveness models in prostate cancer: exploring new developments in testing and diagnosisSemantic proximity Read

Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature.Semantic proximity Read

Methodological Challenges in Dutch HTA of Non-Oncological Orphan Drugs: A Retrospective Analysis and Price Comparison Using different Pricing ModelsSemantic proximity Read

Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.Semantic proximity Read

Cost-utility analysis of genomic profiling in early breast cancer in ColombiaSemantic proximity Read